TWEET by @CellCentric
New paper: p300/CBP inhibition to treat lymphoma. From our collaboration with Laura Pasqualucci: cell.com/immunity/fullt… pic.twitter.com/BDPeRaRHqV
TWEET by @CellCentric
Many thanks to the team at The Christie Hospital. Now dosing blood cancer patients with CCS1477. cellcentric.com/updates/press-… pic.twitter.com/5UQXYjWdAR
TWEET by @CellCentric
Major milestone. Now dosing patients with p300/CBP inhibitor, CCS1477 to treat blood cancers: cellcentric.com/updates/press-… pic.twitter.com/1fm5cHeAzL
TWEET by @CellCentric
CCS1477 prostate cancer (mCRPC) clinical testing continues to scale up, and further sites in the coming months. pic.twitter.com/393YhVbKwB
TWEET by @CellCentric
Inhibiting p300/CBP disrupts key pathways involved in cancer progression and can also address tumour drug resistance. pic.twitter.com/FbyUuWSgvD
TWEET by @CellCentric
CellCentric NW moving soon to new space, as our clinical development team and activities expand. pic.twitter.com/IIih0uMWxj
